APG-2449

Phase 1Small molecule

APG-2449 is one of 3 small molecule programs targeting Platinum-resistant Recurrent Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platinum-Resistant Recurrent Ovarian CancerRecruiting

Advanced Solid CancerRecruiting

Platinum-Resistant Recurrent Ovarian CancerPhase 1

Recruiting

Advanced Solid CancerPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Advanced Solid Cancer

#DrugCompanyPhaseTrials

Ezabenlimab

Boehringer Ingelheim

Phase 1

1 2

SHR-A1904

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1

1 3

APG-2449

Ascentage Pharma Group Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Advanced Solid Cancer

NCT03917043

Q2 2028

Phase 1Recruiting

Platinum-Resistant Recurrent Ovarian Cancer

NCT06687070

Clinical

Trials by Indication[1]

Advanced Solid Cancer1 trial

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT03917043·165 enrolled

Platinum-resistant Recurrent Ovarian Cancer1 trial

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT06687070·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for APG-2449. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APG-2449 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APG-2449. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ascentage Pharma Group Inc.

APG-2449

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Trials by Indication[1]

Advanced Solid Cancer1 trial

Platinum-resistant Recurrent Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News